Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Ribrag

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
Leukemia|March 3, 2006
High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL)E Jabbour, S Koscielny, C Sebban, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 8, 2023
Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 casesA Gueiderikh, M Ung, J Lazarovici, et al.
Cancer Genetics and Cytogenetics|May 14, 2003
Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse modelR M'kacher, F Farace, A Bennaceur-Griscelli, et al.
International Journal of Radiation Oncology, Biology, Physics|August 23, 2001
A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatmentT Girinsky, D Guillot-Vals, S Koscielny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 2007
Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic typeP Pautier, V Ribrag, P Duvillard, et al.
Bone Marrow Transplantation|June 19, 1998
VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's diseaseV Ribrag, F Nasr, J H Bouhris, et al.
Cancer Chemotherapy and Pharmacology|June 24, 2023
Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patientsM Valery, K Saleh, R Ecea, et al.
Leukemia & Lymphoma|August 1, 1997
Mantle cell lymphomas: characteristics, natural history and prognostic factors of 45 casesD Decaudin, J Bosq, J N Munck, et al.
European Journal of Cancer (Oxford, England : 1990)|April 11, 2018
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumoursH Herin, S Aspeslagh, E Castanon, et al.
Oncogene|September 13, 2003
Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphomaR M'kacher, A Bennaceur, F Farace, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
Leukemia|March 3, 2006
High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL)E Jabbour, S Koscielny, C Sebban, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 8, 2023
Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 casesA Gueiderikh, M Ung, J Lazarovici, et al.
Cancer Genetics and Cytogenetics|May 14, 2003
Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse modelR M'kacher, F Farace, A Bennaceur-Griscelli, et al.
International Journal of Radiation Oncology, Biology, Physics|August 23, 2001
A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatmentT Girinsky, D Guillot-Vals, S Koscielny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 2007
Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic typeP Pautier, V Ribrag, P Duvillard, et al.
Bone Marrow Transplantation|June 19, 1998
VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's diseaseV Ribrag, F Nasr, J H Bouhris, et al.
Cancer Chemotherapy and Pharmacology|June 24, 2023
Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patientsM Valery, K Saleh, R Ecea, et al.
Leukemia & Lymphoma|August 1, 1997
Mantle cell lymphomas: characteristics, natural history and prognostic factors of 45 casesD Decaudin, J Bosq, J N Munck, et al.
European Journal of Cancer (Oxford, England : 1990)|April 11, 2018
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumoursH Herin, S Aspeslagh, E Castanon, et al.
Oncogene|September 13, 2003
Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphomaR M'kacher, A Bennaceur, F Farace, et al.
Pageof 10